CURA:CA:TSX-Curaleaf Holdings Inc. (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

CAD 2.31

Change

0.00 (0.00)%

Market Cap

CAD 1.61B

Volume

0.31M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
BHC:CA Bausch Health Companies Inc

-0.07 (-0.62%)

CAD 3.94B
TLRY:CA Tilray Inc

-0.06 (-2.87%)

CAD 1.89B
CRON:CA Cronos Group Inc

-0.10 (-3.34%)

CAD 1.07B
DHT-UN:CA DRI Healthcare Trust

+0.08 (+0.69%)

CAD 0.75B
WEED:CA Canopy Growth Corp

-0.05 (-1.18%)

CAD 0.60B
AOV:CA Amotiv Limited

+0.05 (+0.93%)

CAD 0.58B
GUD:CA Knight Therapeutics Inc.

+0.05 (+0.93%)

CAD 0.58B
DHT-U:CA DRI Healthcare Trust

-0.01 (-0.12%)

CAD 0.54B
CPH:CA Cipher Pharmaceuticals Inc

+0.21 (+1.46%)

CAD 0.38B
ACB:CA Aurora Cannabis Inc

-0.14 (-2.06%)

CAD 0.36B

ETFs Containing CURA:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.13% 43% F 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.13% 43% F 85% B
Trailing 12 Months  
Capital Gain -62.98% 10% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.98% 10% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -15.95% 32% F 3% F
Dividend Return -15.95% 32% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.30% 55% F 22% F
Risk Adjusted Return -39.57% 32% F 7% C-
Market Capitalization 1.61B 91% A- 75% C

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.